pioglitazone has been researched along with Aortic Stenosis in 4 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Valvular inflammation triggered by hyperlipidemia has been considered as an important initial process of aortic valve disease; however, cellular and molecular evidence remains unclear." | 1.72 | Single-cell transcriptomics reveal cellular diversity of aortic valve and the immunomodulation by PPARĪ³ during hyperlipidemia. ( Ahn, HS; Ann, SJ; Choi, JH; Chung, J; Go, DM; Han, I; Jeong, SC; Kim, DY; Kim, K; Kim, KW; Kim, M; Kim, N; Kim, TK; Lee, HO; Lee, S; Lee, SH; Lee, SP; Oh, GT; Park, J; Park, JH; Park, KS; Park, SE; Park, WY; Shim, D; Woo, SH; Yoon, WK; Zhang, JY, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 2 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Katahira, S | 1 |
| Sugimura, Y | 1 |
| Grupp, S | 1 |
| Doepp, R | 1 |
| Selig, JI | 1 |
| Barth, M | 1 |
| Lichtenberg, A | 1 |
| Akhyari, P | 1 |
| Lee, SH | 3 |
| Kim, N | 1 |
| Kim, M | 1 |
| Woo, SH | 1 |
| Han, I | 1 |
| Park, J | 1 |
| Kim, K | 2 |
| Park, KS | 1 |
| Shim, D | 1 |
| Park, SE | 1 |
| Zhang, JY | 1 |
| Go, DM | 1 |
| Kim, DY | 1 |
| Yoon, WK | 1 |
| Lee, SP | 1 |
| Chung, J | 1 |
| Kim, KW | 1 |
| Park, JH | 1 |
| Lee, S | 1 |
| Ann, SJ | 1 |
| Ahn, HS | 1 |
| Jeong, SC | 1 |
| Kim, TK | 1 |
| Oh, GT | 1 |
| Park, WY | 1 |
| Lee, HO | 1 |
| Choi, JH | 1 |
| Li, F | 1 |
| Cai, Z | 1 |
| Chen, F | 1 |
| Shi, X | 1 |
| Zhang, Q | 1 |
| Chen, S | 1 |
| Shi, J | 1 |
| Wang, DW | 1 |
| Dong, N | 1 |
| Chu, Y | 1 |
| Lund, DD | 1 |
| Weiss, RM | 1 |
| Brooks, RM | 1 |
| Doshi, H | 1 |
| Hajj, GP | 1 |
| Sigmund, CD | 1 |
| Heistad, DD | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Pioglitazone Treatment in Patient's Calcific Aortic Valve Disease With Mild Aortic Valve Stenosis[NCT05875675] | Phase 2 | 100 participants (Anticipated) | Interventional | 2023-07-01 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 other studies available for pioglitazone and Aortic Stenosis
| Article | Year |
|---|---|
PPAR-Gamma Activation May Inhibit the In Vivo Degeneration of Bioprosthetic Aortic and Aortic Valve Grafts under Diabetic Conditions.
Topics: Animals; Aorta; Aortic Valve; Aortic Valve Stenosis; Blood Glucose; Body Weight; Calcinosis; Diabete | 2021 |
Single-cell transcriptomics reveal cellular diversity of aortic valve and the immunomodulation by PPARĪ³ during hyperlipidemia.
Topics: Animals; Aortic Valve; Aortic Valve Stenosis; Calcinosis; Cells, Cultured; Endothelial Cells; Humans | 2022 |
Pioglitazone attenuates progression of aortic valve calcification via down-regulating receptor for advanced glycation end products.
Topics: Animals; Aortic Valve; Aortic Valve Stenosis; Calcinosis; Cell Differentiation; Down-Regulation; Dru | 2012 |
Pioglitazone attenuates valvular calcification induced by hypercholesterolemia.
Topics: Adiponectin; Animals; Aorta; Aortic Valve; Aortic Valve Stenosis; Apolipoprotein B-100; Apoptosis; B | 2013 |